$Allogene Therapeutics (ALLO.US)$ NEWS Allogene Therapeutics...
NEWS
Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $22.000 thousand in sales this quarter. This is a 26.67 percent decrease over sales of $30.000 thousand the same period last year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment